Kite Pharma enters into licensing agreement with NIH
Kite Pharma, a biotech company, has entered into a licensing agreement with the US’s National Institute of Health (NIH) that will give it the IP rights to T-cell therapies developed to treat cancer.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
19 May 2022 The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.
19 May 2022 The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.
19 May 2022 The Medicines Patent Pool and World Health Organization’s COVID-19 Technology Access Pool have signed a deal aiming to open up new technologies to people living in poorer countries.